SCHEMBL3018861

SCHEMBL3018861

COc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4c(C(C)C)cc(C(C)C)cc4C(C)C)CC3)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.41
MAPT P10636 2/20 0.41
USP2 O75604 1/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
POLB P06746 2/20 0.40
ATM Q13315 2/20 0.38
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 2/20 0.37
GAA P10253 2/20 0.37
PKM P14618 1/20 0.37
HTT P42858 1/20 0.37
DPP8 Q6V1X1 1/20 0.37
TP53 P04637 2/20 0.37
F2RL3 Q96RI0 2/20 0.37
MAPK1 P28482 1/20 0.37
OGA O60502 1/20 0.37
TSHR P16473 1/20 0.36
PIK3CD O00329 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3645260 0.96 ALDH1A1 (0.42) KMT2AMAPTUSP2RECQLHSD17B10
SCHEMBL3009426 0.92 MEN1 (0.39) KMT2AMAPTUSP2RECQLHSD17B10
SCHEMBL3012065 0.92 MAPT (0.40) KMT2AMAPTUSP2RECQLHSD17B10
SCHEMBL3017999 0.90 MAPT (0.47) KMT2AMAPTUSP2RECQLHSD17B10
SCHEMBL3018377 0.90 ALDH1A1 (0.40) KMT2AMAPTLMNASMN1; SMN2ALDH1A1
SCHEMBL3013519 0.90 OGA (0.39) KMT2AMAPTUSP2RECQLHSD17B10
SCHEMBL3013311 0.89 ALDH1A1 (0.39) MAPTUSP2RECQLHSD17B10POLB
SCHEMBL3006975 0.89 FABP4 (0.42) KMT2AMAPTPOLBLMNASMN1; SMN2
SCHEMBL3017068 0.89 MAPT (0.40) KMT2AMAPTUSP2RECQLHSD17B10
SCHEMBL3022621 0.89 MAPT (0.40) KMT2AMAPTUSP2RECQLHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KMT2A 2680/4885MAPT 18/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.